These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36089211)

  • 21. Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system.
    Chang HY; Wu S; Chowdhury EA; Shah DK
    J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):337-362. PubMed ID: 35092540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics.
    Sayama H; Komura H; Kogayu M; Iwaki M
    J Pharm Sci; 2013 Nov; 102(11):4193-204. PubMed ID: 24018828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PBPK-based translation from preclinical species to humans for the full-size IgG therapeutic efalizumab.
    Franz M; Jairam RK; Kuepfer L; Hanke N
    Front Pharmacol; 2024; 15():1418870. PubMed ID: 39411068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiologically based pharmacokinetics (PBPK).
    Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
    Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.
    Chang HP; Li Z; Shah DK
    Pharm Res; 2022 Jan; 39(1):1-24. PubMed ID: 35044590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems.
    Graf JF; Scholz BJ; Zavodszky MI
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):37-54. PubMed ID: 22161221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A PBPK Model of Ternary Cyclodextrin Complex of ST-246 Was Built to Achieve a Reasonable IV Infusion Regimen for the Treatment of Human Severe Smallpox.
    Zhang Z; Fu S; Wang F; Yang C; Wang L; Yang M; Zhang W; Zhong W; Zhuang X
    Front Pharmacol; 2022; 13():836356. PubMed ID: 35370741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins.
    Liu S; Li Y; Li Z; Wu S; Harrold JM; Shah DK
    J Pharmacokinet Pharmacodyn; 2024 Oct; 51(5):449-476. PubMed ID: 38691205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful Prediction of Human Pharmacokinetics by Improving Calculation Processes of Physiologically Based Pharmacokinetic Approach.
    Mayumi K; Ohnishi S; Hasegawa H
    J Pharm Sci; 2019 Aug; 108(8):2718-2727. PubMed ID: 30876861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole-Body Physiologically Based Pharmacokinetic Modeling of Trastuzumab and Prediction of Human Pharmacokinetics.
    Bae DJ; Kim SY; Bae SM; Hwang AK; Pak KC; Yoon S; Lim HS
    J Pharm Sci; 2019 Jun; 108(6):2180-2190. PubMed ID: 30716331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
    Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
    Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen.
    Loisios-Konstantinidis I; Cristofoletti R; Jamei M; Turner D; Dressman J
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33147873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data.
    Poirier A; Cascais AC; Funk C; Lavé T
    Chem Biodivers; 2009 Nov; 6(11):1975-87. PubMed ID: 19937834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy.
    Pierrillas PB; Henin E; Ball K; Ogier J; Amiel M; Kraus-Berthier L; Chenel M; Bouzom F; Tod M
    Drug Metab Dispos; 2019 Jun; 47(6):648-656. PubMed ID: 30940629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats.
    Sepp A; Meno-Tetang G; Weber A; Sanderson A; Schon O; Berges A
    J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):339-359. PubMed ID: 31079322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn.
    Chen Y; Balthasar JP
    AAPS J; 2012 Dec; 14(4):850-9. PubMed ID: 22956476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translation of Monoclonal Antibodies Pharmacokinetics from Animal to Human Using Physiologically Based Modeling in Open Systems Pharmacology (OSP) Suite: A Retrospective Analysis of Bevacizumab.
    Pasquiers B; Benamara S; Felices M; Ternant D; Declèves X; Puszkiel A
    Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.
    Li GF; Wang K; Chen R; Zhao HR; Yang J; Zheng QS
    Acta Pharmacol Sin; 2012 Nov; 33(11):1359-71. PubMed ID: 23085739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.